World Biological Therapy: Indolent Lymphoma – Pipeline Review, H1 2012

• Publication date: April 2013
• Report size: 100 pages

This report provides data on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. 'Indolent Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings...

This report provides data on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. 'Indolent Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.



Scope of the Research


- A snapshot of the global therapeutic scenario for Indolent Lymphoma.
- A review of the Indolent Lymphoma products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Indolent Lymphoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage new product development featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.



Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Indolent Lymphoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Indolent Lymphoma pipeline depth and focus of Indolent Lymphoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Therapy Industry

Table of Contents
Data table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global March kets Direct Report Coverage 7
Indolent Lymphoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Indolent Lymphoma 9
Indolent Lymphoma Therapeutics under Development by Firms 11
Indolent Lymphoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Indolent Lymphoma Therapeutics – Products under Development by Firms 19
Indolent Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Indolent Lymphoma Therapeutics Development 22
F. Hoffmann-La Roche Ltd. 22
Abbott Laboratories 23
Sanofi-Aventis 24
GlaxoSmithKline plc 25
Gilead Sciences, Inc. 26
Cephalon, Inc. 27
Pfizer Inc. 28
Cell Therapeutics, Inc. 29
Celgene Corporation 30
Accentia Biopharmaceuticals, Inc. 31
Mundipharma International Limited 32
S*BIO Pte Ltd 33
Astellas Pharma GmbH 34
Indolent Lymphoma – Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
RG7159 - Drug Profile 41
Pacritinib - Drug Profile 42
BiovaxID - Drug Profile 44
Bendamustine Hydrochloride - Drug Profile 46
GS-1101 - Drug Profile 48
Rituximab + Gemcitabine + Oxaliplatin - Drug Profile 50
Rituxan + BEAM + Autologous Stem Cell Transplantation - Drug Profile 51
PS-341 + Alvocidib - Drug Profile 52
VR-CHOP - Drug Profile 53
RAD001 + Velcade - Drug Profile 55
Rituximab - Drug Profile 57
Velcade + Rituximab - Drug Profile 58
Rituximab + Dexamethasone - Drug Profile 59
Vorinostat - Drug Profile 61
CMC-544 - Drug Profile 63
Treanda + Rituxan - Drug Profile 64
GS 1101 + Bendamustine + Rituximab - Drug Profile 66
GS 1101 + Bendamustine - Drug Profile 68
GS-1101 + Rituximab - Drug Profile 69
RG7159 + Bendamustine - Drug Profile 71
Arzerra + Bendamustine - Drug Profile 73
RG7159 + CHOP - Drug Profile 75
Pixuvri + Fludarabine + Dexamethasone + Rituximab - Drug Profile 78
Zevalin + Rituximab - Drug Profile 80
Dolastatin 10 - Drug Profile 81
Velcade + BEAM + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 82
Vorinostat + Rituximab - Drug Profile 84
Proleukin + Cyclophosphamide + Therapeutic Autologous Lymphocytes - Drug Profile 85
Tumor Derived Immunoglobulin Idiotype With Keyhole Limpet Hemocyanin Conjugate Vaccine + Sargramostim + Cyclophosphamide + Vincristine + Prednisone + Doxorubicin - Drug Profile 87
Treanda + Ofatumumab - Drug Profile 90
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 91
Rituximab + THP-COP - Drug Profile 93
Interleukin-4 - Drug Profile 95
Rituxan + Doxil - Drug Profile 97
Rituximab + Velcade + Cladribine - Drug Profile 98
Rituximab + Bortezomib + Cyclophosphamide + Prednisone - Drug Profile 99
Pegfilgrastim + Rituximab - Drug Profile 101
Recombinnat Interferon Alfa + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate - Drug Profile 102
Rituximab + PS-341 + Fludarabine - Drug Profile 104
Rituximab + Zevalin - Drug Profile 106
Proleukin + Therapeutic Autologous Lymphocytes + Cyclophosphamide + Prednisone + Vincristine Sulfate - Drug Profile 107
Rituximab + Lenalidomide - Drug Profile 109
Rituximab + Bendamustine + Obatoclax - Drug Profile 111
Rituximab + Bendamustine - Drug Profile 112
Ofatumumab - Drug Profile 113
Bendamustine - Drug Profile 114
Revlimid + Rituxan - Drug Profile 115
Ofatumumab - Drug Profile 116
Zevalin + Rituxan - Drug Profile 117
TRU-016 + Rituximab + Bendamustine - Drug Profile 119
RO5072759 + Chemotherapy - Drug Profile 121
Allogeneic Haematopoietic Stem Cell Transplantation + Fludarabine + Radiation Therapy - Drug Profile 123
GS 1101 + Ofatumumab - Drug Profile 124
GS 1101 + Fludarabine - Drug Profile 125
SAR245409 + Rituximab - Drug Profile 126
SAR245409 + Bendamustine + Rituximab - Drug Profile 128
SAR245409 + Bendamustine - Drug Profile 129
Fludarabine + Cyclophosphamide - Drug Profile 130
Indolent Lymphoma Therapeutics – Drug Profile Updates 131
Indolent Lymphoma Therapeutics – Discontinued Products 143
Indolent Lymphoma Therapeutics - Dormant Products 144
Indolent Lymphoma – Product Development Milestones 145
Featured News & Press Releases 145
Appendix 151
Methodology 151
Coverage 151
Secondary Research 151
Primary Research 151
Expert Panel Validation 151
Contact Us 152
Disclaimer 152

List of Tables

Number of Products Under Development for Indolent Lymphoma, H1 2012 13
Products under Development for Indolent Lymphoma – Comparative Analysis, H1 2012 14
Number of Products under Development by Firms, H1 2012 16
Number of Products under Investigation by Universities/Institutes, H1 2012 18
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 19
Comparative Analysis by Late Stage Development, H1 2012 20
Comparative Analysis by Mid Clinical Stage Development, H1 2012 21
Comparative Analysis by Early Clinical Stage Development, H1 2012 22
Products under Development by Firms, H1 2012 23
Products under Investigation by Universities/Institutes, H1 2012 24
F. Hoffmann-La Roche Ltd., H1 2012 26
Abbott Laboratories, H1 2012 27
Sanofi-Aventis, H1 2012 28
GlaxoSmithKline plc, H1 2012 29
Gilead Sciences, Inc., H1 2012 30
Cephalon, Inc., H1 2012 31
Pfizer Inc., H1 2012 32
Cell Therapeutics, Inc., H1 2012 33
Celgene Corporation, H1 2012 34
Accentia Biopharmaceuticals, Inc., H1 2012 35
Mundipharma International Limited, H1 2012 36
S*BIO Pte Ltd, H1 2012 37
Astellas Pharma GmbH, H1 2012 38
Assessment by Monotherapy Products, H1 2012 39
Assessment by Combination Products, H1 2012 40
Assessment by Stage and Route of Administration, H1 2012 42
Assessment by Stage and Molecule Type, H1 2012 44
Indolent Lymphoma Therapeutics – Drug Profile Updates 135
Indolent Lymphoma Therapeutics – Discontinued Products 147
Indolent Lymphoma Therapeutics – Dormant Products 148

List of Figures

Number of Products under Development for Indolent Lymphoma, H1 2012 13
Products under Development for Indolent Lymphoma – Comparative Analysis, H1 2012 14
Products under Development by Firms, H1 2012 15
Products under Investigation by Universities/Institutes, H1 2012 17
Late Stage Products, H1 2012 20
Mid Clinical Stage Products, H1 2012 21
Early Clinical Stage Products, H1 2012 22
Assessment by Monotherapy Products, H1 2012 39
Assessment by Combination Products, H1 2012 40
Assessment by Route of Administration, H1 2012 41
Assessment by Stage and Route of Administration, H1 2012 42
Assessment by Molecule Type, H1 2012 43
Assessment by Stage and Molecule Type, H1 2012 44